Heart Defect Procedure Reduces Stroke By 73%Main Category: Stroke
Also Included In: Cardiovascular / Cardiology
Article Date: 22 Mar 2013
A procedure to close a heart defect that most people are born with can decrease the risk of recurrent stroke by 73 percent, according to new data published in the New England Journal of Medicine.
The findings came from an eight year study called the RESPECT trial (Randomized Evaluation of recurrent Stroke comparing PFO closure to Established Current standard of care Treatment). It was made to test the superiority of the AMPLATZER PFO device in the treatment of cryptogenic stroke patients compared with current medical management.
In a healthy developing fetus, the foramen oval permits oxygenated blood from the placenta to skip over the lungs. This small, flap-like entrance generally closes immediately after birth. However, when the flap stays open or patent - it is called a patent foramen oval (PFO).
A PFO can sometimes let dangerous clots go from the right side of the heart to the left, move up to the brain, and result in a stroke. Treatment normally consists of a minimally-invasive procedure conducted by a cardiologist to permanently close the PFO.
A Handy Device That Closes The PassagewayThe device used during the study - AMPLATZER PFO Occluder - is a double-disc device made of polyester fabric and Nitinol mesh. It is placed into the PFO to close the passageway between the left and right atria. The device is successful in preventing a clot from traveling from one side to the other and possibly to the brain where it can result in a stroke.
The current trial revealed that the device safely closed the PFO. No differences were seen between medical management and device treatment in the incidence of:
The RESPECT TrialThe trial aimed to determine the most effective treatment for patients with cryptogenic stroke. The trial started in 2003 and recruited 980 patients from 69 medical centers in Canada and the U.S.
All participants had suffered a stroke verified by MRI and categorized as cryptogenic before starting the trial. The patients' average age was 46 years .
The subjects were randomly assigned to one of two groups. One group received the AMPLATZER PFO Occluder and standard of care medical management. The second group was treated using the current standard of care alone. Patients were analyzed at one, six, twelve, eighteen, and twenty-four months, and yearly after that.
AMPLATZER PFO Proven EffectiveResults revealed that the device:
Additionally, another study suggested that antioxidants do not have a positive effect on preventing diseases like dementia and stroke, contradicting other previous research.
Written by Kelly Fitzgerald
Copyright: MediLexicon International Ltd
Original article posted on Medical News Today.
Articles not to be reproduced without permission of Medical News Today